Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
Status:
Completed
Trial end date:
2018-06-29
Target enrollment:
Participant gender:
Summary
This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of
multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary
Sjögren's syndrome(pSS)